Recent Press Releases

Portola Pharmaceuticals Announces Phase 3 ANNEXA(TM)-A Study of Andexanet Alfa and Eliquis (Apixaban) Met Primary and Secondary Endpoints With High Statistical Significance

Detailed Data Showing Andexanet Alfa Significantly Reversed Anticoagulation Activity of Factor Xa Inhibitor Eliquis to be Featured at American Heart Association's "Clinical Science: Special...

Valeant Pharmaceuticals' Bridgewater Location Receives Warning Letter From FDA

LAVAL, Quebec, Sep. 30, 2014 (Canada NewsWire via COMTEX) -- Valeant Pharmaceuticals International, Inc. today announced that the company's Bridgewater, New Jersey location received a Warning...

GE Healthcare to Collaborate with GlaxoSmithKline on Commercial Oncology Testing

GE Healthcare to Collaborate with GlaxoSmithKline on Commercial Oncology Testing ALISO VIEJO, Calif., Sep 30, 2014 (BUSINESS WIRE) -- GE Healthcare today announced an agreement between its affiliate,...

Johnson & Johnson Announces Agreement To Acquire Alios BioPharma

Acquisition Strengthens Existing Pipeline in Viral Diseases

NEW BRUNSWICK, N.J., Sept.

Frost & Sullivan applauds the diversity of Ventana products and services for the cancer diagnostics market

Ventana is committed to accelerating the discovery and development of new cancer diagnostic tests that help determine the best course of therapy for each individual patient.

Vaccine Manufacturing Technology and Services: World Market Forecast 2014-2024

Prospects For Leading Players

NEW YORK, Sept. 30, 2014 /PRNewswire/ -- Report Details

RE: public launch of the Open Payments website

September 29, 2014 Marilyn Tavenner Administrator Centers for Medicare & Medicaid Services (CMS) Department of Health and Human Services 200 Independence Avenue, SW Washington, DC 20201 RE:...

MSF URGES PRIME MINISTER MODI TO RESIST U.S. POLITICAL PRESSURE TO RESTRICT GLOBAL ACCESS TO MEDICINES

NEW DELHI/NEW YORK, SEPTEMBER 26, 2014 – As Indian Prime Minister Narendra Modi makes his first official visit to the United States, Doctors Without Borders/Médecins Sans...

FDA Approves RELISTOR® Subcutaneous Injection for the Treatment of Opioid-Induced Constipation in Patients with Chronic Non-cancer Pain

FDA Approves RELISTOR® Subcutaneous Injection for the Treatment of Opioid-Induced Constipation in Patients with Chronic Non-cancer Pain Marketing Approval Expands Treatment to Include Nearly 11...

Lilly's seventh Global Day of Service rallies 24,000 employees in nearly 60 countries

INDIANAPOLIS, Sept. 29, 2014 /PRNewswire/ -- On Oct.

NanoLogix Technology Cited In UNITAID Annual Report On TB, Through The World Health Organization

The Ohio State University Issues Purchase Order For Lab Supplies To NanoLogix

European Medicines Agency Validates the Marketing Authorization Application for Nivolumab in Non-Small Cell Lung Cancer

European Medicines Agency Validates the Marketing Authorization Application for Nivolumab in Non-Small Cell Lung Cancer PRINCETON, N.J., Sep 29, 2014 (BUSINESS WIRE) -- Bristol-Myers Squibb Company...

Positive Phase 3 Data for Opdivo (nivolumab) in Advanced Melanoma Patients Previously Treated with Yervoy (ipilimumab) Presented at the ESMO 2014 Congress; First Phase 3 Results Presented for a PD-1 Immune Checkpoint Inhibitor

Positive Phase 3 Data for Opdivo (nivolumab) in Advanced Melanoma Patients Previously Treated with Yervoy (ipilimumab) Presented at the ESMO 2014 Congress; First Phase 3 Results Presented for a PD-1...

Crizotinib treatment effective against ROS1-positive lung cancer

Crizotinib treatment effective against ROS1-positive lung cancer Treatment led to significant tumor shrinkage in 72 percent of treated patients Treatment with the targeted therapy drug crizotinib...

Pfizer Completes Acquisition Of InnoPharma

Pfizer Completes Acquisition Of InnoPharma Thursday, September 25, 2014 - 8:00am EDT Pfizer Inc. (NYSE:PFE) today announced that it has completed its acquisition of the pharmaceutical development...

Merck Announces First Presentation of Early Data on the Investigational Use of KEYTRUDA® (pembrolizumab) in Patients with Advanced Bladder Cancer at ESMO 2014

Merck Announces First Presentation of Early Data on the Investigational Use of KEYTRUDA® (pembrolizumab) in Patients with Advanced Bladder Cancer at ESMO 2014 KEYTRUDA® monotherapy achieved...

GSK announces overall survival results from phase III BREAK-3 study of Tafinlar® (dabrafenib) in patients with BRAF V600E-mutant metastatic melanoma

GSK announces overall survival results from phase III BREAK-3 study of Tafinlar® (dabrafenib) in patients with BRAF V600E-mutant metastatic melanoma 29 September 2014 Issued: London, UK GSK today...

Novartis drug Afinitor is first treatment for advanced pancreatic NET to provide overall survival of more than 3.5 years in Phase III trial

Novartis drug Afinitor is first treatment for advanced pancreatic NET to provide overall survival of more than 3.5 years in Phase III trial Afinitor led to an unprecedented median overall survival of...

Patients lived average of 18 months without cancer progressing when taking Novartis' Zykadia(TM) as their first ALK inhibitor for ALK+ NSCLC

Patients lived average of 18 months without cancer progressing when taking Novartis' Zykadia(TM) as their first ALK inhibitor for ALK+ NSCLC Longest median progression-free survival (PFS) ever...

Roche's investigational combination of cobimetinib plus Zelboraf (vemurafenib) provided significant benefit to people with advanced melanoma over Zelboraf alone

Roche's investigational combination of cobimetinib plus Zelboraf (vemurafenib) provided significant benefit to people with advanced melanoma over Zelboraf alone • Cobimetinib plus Zelboraf...